- Home
- CGO vs UNCY Comparison
CGO vs UNCY Comparison
Compare CGO & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CGO | UNCY |
|---|---|---|
| Founded | 2004 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 129.6M | 150.1M |
| IPO Year | 2004 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CGO | UNCY |
|---|---|---|
| Price | $13.09 | $5.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $25.67 |
| AVG Volume (30 Days) | 27.7K | ★ 695.7K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | ★ 9.25% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $582.86 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.71 | $3.72 |
| 52 Week High | $14.20 | $8.74 |
Technical Indicators
Market Signals| Indicator | CGO | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 47.52 | 41.66 |
| Support Level | $12.96 | $4.81 |
| Resistance Level | $13.71 | $5.86 |
| Average True Range (ATR) | 0.28 | 0.24 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 20.00 | 4.94 |
Price Performance
Historical ComparisonAbout CGO Calamos Global Total Return Fund
Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in equities, convertible securities, and high-yield corporate bonds.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.